Abstracts Archive - Page 233 of 2425 - ACR Meeting Abstracts

Abstract Number: 0765 • ACR Convergence 2023
RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives
Guy Katz¹, Melissa Briones², Nina Couette³, Meridith Balbach⁴, Sabahat Usmani⁵, Lauren He⁶, Michael Macklin⁶, Iman Qaiser⁷, John Kellogg⁸, Courtney Bair⁸, Benjamin Lueck⁸, Akrithi Garren⁹, Matthew Sparks⁸, Lisa Criscione-Schreiber⁸ and David Leverenz⁸, ¹Massachusetts General Hospital, Boston, MA, ²Loyola University, Maywood, IL, ³Genesis Healthcare System, Columbus, OH, ⁴Vanderbilt University Medical Center, Nashville, TN, ⁵Weiss Memorial Hospital, Chicago, IL, ⁶University of Chicago, Chicago, IL, ⁷Louisiana State University, Shreveport, LA, ⁸Duke University School of Medicine, Durham, NC, ⁹MedStar/Georgetown Washington Hospital Center, Silver Spring, MD
Background/Purpose: RheumMadness is an online tournament of rheumatology concepts that has been shown to engage learners using the Community of Inquiry (CoI) framework. theMednet is…
Abstract Number: 0759 • ACR Convergence 2023
Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry
Piero Ruscitti¹, Antonio Vitale², Ilenia Di Cola¹, Roberto giacomelli³ and Luca Cantarini⁴, ¹University of L'Aquila, L'Aquila, Italy, ²University of Siena, Siena, Italy, ³University of Rome Campus Biomedico, Rome, Italy, ⁴Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy
Background/Purpose: Still's disease is a rare inflammatory disorder, these patients have a highly heterogeneous disease according to age of onset, clinical presentation, presence of life-threatening…
Abstract Number: 0758 • ACR Convergence 2023
Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease
STEPHANE MITROVIC¹, Arianna De Matteis², Sara Bindoli³, Fabrizio De Benedetti⁴, Bruno Fautrel⁵, Loreto Carmona⁶ and On Behalf Of The Eular/PreS QoC011 Task Force Member⁷, ¹Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, ²IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ³Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, ⁴Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ⁵Sorbonne Université APHP, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) are part of the non-familial (sporadic) systemic inflammatory disorders and are frequently mentioned as…
Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Roba Ghossan¹, Omar AL TABAA², Alice Combier³, Alexia STEELANDT³, Marion THOMAS³, Olivier Fogel³, Corinne MICELI⁴, Anna Molto³ and Jérôme Avouac⁵, ¹COCHIN HOSPITAL, Paris, France, ²APHP / Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…
Abstract Number: 0766 • ACR Convergence 2023
The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis
Valentin Sebastian Schäfer¹, Tobias Schremmer², Florian Recker³, Wolfgang Hartung⁴, Christina Duftner⁵, Sara Monti⁶, Alojzija Hocevar⁷, Rositsa Karalilova⁸, Annamaria Iagnocco⁹, PIERLUIGI MACCHIONI¹⁰, Giuseppe Antonio Germano¹¹, Maria Esperanza Naredo Sanchez¹², Eugenio De Miguel¹³, Luca Seitz¹⁴, Thomas Daikeler¹⁵, Markus Aschwanden¹⁶, Dennis Boumans¹⁷, Chetan Mukhtyar¹⁸, smith kate¹⁹, Richard Wakefield²⁰, Andreas Diamantopoulos²¹, Stavros Chrysidis²², Berit Dalsgaard Nielsen²³, Kresten Keller²⁴, Uffe Dohn²⁵, Lene Terslev²⁶, Marcin Milchert²⁷, Aaron Juche²⁸, Wolfgang Schmidt²⁹, George A. W. Bruyn³⁰ and Christian Dejaco³¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²Universitätsklinikum Bonn, Bonn, Germany, ³Department for Gynecology and Obstetrics, University Hospital Bonn, Bonn, Germany, ⁴Asklepios Clinic, Tegernheim, Germany, ⁵Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁶Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁷Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, ⁹University of Turin, Roma, Italy, ¹⁰Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ¹¹Rheumatology Unit- Arcispedale Santa Maria Nuova Reggio Emilia-Italy, Reggio Emilia, Italy, ¹²Rheumatology Department and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ¹⁵Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ¹⁶Department of Angiology, University Hospital Basel, Basel, Switzerland, ¹⁷Rheumatology and Clinical Immunology, Hospital Group Twente, Almelo, Netherlands, ¹⁸Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁹NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²⁰s Leeds Insitute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²¹Akershus University Hospital, Lørenskog, Norway, ²²Department of Rheumatology, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark, ²³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, The Regional Hospital in Horsens, Horsens, Denmark, ²⁴Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²⁵Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, ²⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ²⁷Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²⁸Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ²⁹Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ³⁰Reumakliniek Lelystad, Loenga, Netherlands, ³¹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Ultrasonography has been validated as a diagnostic tool for giant cell arteritis (GCA). There is a need to develop training resources, because the glucocorticoid…
Abstract Number: 0673 • ACR Convergence 2023
Reporting of Race, Ethnicity, Sex, Gender, Socioeconomic Status and Representativeness of Race and Ethnicity in ANCA-associated Vasculitis Randomized Trials
Michele Iudici¹, Juan C. Rueda² and Xavier Puéchal³, ¹Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ²Universidad de La Sabana, Chía, Colombia, Chia, Colombia, ³National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France
Background/Purpose: To assess how and to what extent race, ethnicity, sex, gender and socioeconomic status of participants are reported in ANCA-associated vasculitis (AAV) randomized controlled…
Abstract Number: 0772 • ACR Convergence 2023
MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Klein¹, Austin Wheeler¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, K Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Dana Ascherman⁶, Gary Kunkel⁷, Grant Cannon⁸, Paul Monach⁹, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls¹⁰ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The gain of function MUC5B rs35705950 promoter variant is the strongest genetic risk factor for the development of RA-ILD (specific to a usual interstitial…
Abstract Number: 0785 • ACR Convergence 2023
Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie M. Bartels³, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of lupus (or SLE) treatment. Yet the optimal dosing of HCQ in SLE is unknown. Reducing HCQ dose to…
Abstract Number: 0754 • ACR Convergence 2023
Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis
Agnes Loiojen¹, Elise van Mulligen², Annette van der Helm-van Mil³ and Pascal de Jong², ¹Erasmus Medical Center, department of rheumatology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the treatment and follow-up of rheumatoid arthritis (RA) patients, it has become more desirable to detect changes in disease activity through remote monitoring.…
Abstract Number: 0781 • ACR Convergence 2023
Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Amit Saxena¹, Peter Izmirly², Jammie Law³, Cristina Sorrento³, H Michael Belmont⁴ and Jill Buyon⁵, ¹New York University Grossman School of Medicine, Rheumatology, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…
Abstract Number: 0761 • ACR Convergence 2023
EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD)
Bruno Fautrel¹, STEPHANE MITROVIC², Arianna De Matteis³, Sara Bindoli⁴, Jordi Anton⁵, Alexandre Belot⁶, Claudia Bracaglia³, Tamas Constantin⁷, Lorenzo Dagna⁸, Alessandro de Bartolo⁹, Eugen Feist¹⁰, Dirk Foell¹¹, Marco Gattorno¹², Sophie Georgin-Lavialle¹³, Roberto Giacomelli¹⁴, Alexei Grom¹⁵, Yvan Jamilloux¹⁶, Katerina Laskari¹⁷, Calin Lazar¹⁸, Francesca Minoia¹⁹, Peter Nigrovic²⁰, Filipa Oliveira Ramos²¹, Seza Ozen²², Pierre Quartier Dit Maire²³, Piero Ruscitti²⁴, Erdal Sag²⁵, Sinisa Savic²⁶, Marie-Elise Truchetet²⁷, Sebastiaan Vastert²⁸, Tanita Wilhelmer²⁹, Carine Wouters³⁰, Loreto Carmona³¹ and Fabrizio De Benedetti³², ¹Sorbonne Université APHP, Paris, France, ²Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, ³IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ⁴Rheumatology Unit, department of Medicine,University of Padova, Padova, Italy, ⁵Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ⁶Hospices Civils de Lyon, Collonges au mont d'or, France, ⁷Semmelweis University, Budapest, Hungary, ⁸Ospedale San Raffaele, Milano, Italy, ⁹PReS Patient Research Partner, Milan, Italy, ¹⁰Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ¹¹University Hospital Münster, Münster, Germany, ¹²UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹³AP-HP, Tenon hospital, Paris, France, ¹⁴Policlinico Universitario Campus Bio-Medico, Roma, Italy, ¹⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Hospices Civils de Lyon, Lyon, France, ¹⁷Athens University Medical School, Athens, Greece, ¹⁸University of Medicine and Pharmacy, Cluj-Napoca, Romania, ¹⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ²⁰Boston Children's Hospital, Boston, MA, ²¹Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ²²Hacettepe University Medical Faculty, Ankara, Turkey, ²³Necker Hospital, Paris Cedex 15, France, ²⁴University of L'Aquila, L'Aquila, Italy, ²⁵Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ²⁶Leeds University, Leeds, United Kingdom, ²⁷Bordeaux University Hospital, Bordeaux, France, ²⁸University Medical Center Utrecht, Utrecht, Netherlands, ²⁹EULAR Patient Research Partner, Bludenz, Austria, ³⁰Leuven University, Leuven, Belgium, ³¹Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ³²Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) are supposed to be age counterparts of the same disease, but no consensus has…
Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
SOKO KAWASHIMA¹, Yoshinori Komagata¹, Mitsumasa Kishimoto² and Shinya Kaname¹, ¹Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…
Abstract Number: 0790 • ACR Convergence 2023
Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)
Yehya Al-Adwi¹, Johanna Westra¹, Harry van Goor¹, Leon.C.L.T van Kempen², Wim Timens¹, C.Tji Gan¹ and Douwe J Mulder¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²UMCG and University of Antwerp, Groningen, Netherlands
Background/Purpose: SSc-ILD is the leading cause of death in SSc affecting around 50% of the patients. Lung tissue of patients with early-stage SSc-ILD is characterized…
Abstract Number: 0769 • ACR Convergence 2023
Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort
Austin Wheeler¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, K Wysham³, Grant Cannon⁴, Gary Kunkel⁵, Gail Kerr⁶, Dana Ascherman⁷, Paul Monach⁸, Andreas Reimold⁹, Jill Poole¹, Tony Merriman¹⁰, Ted R Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Texas Southwestern Medical Center, Dallas, TX, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Although some clinical and genetic risk…
Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Jose Luis Martin-Varillas³, Carmen Alvarez Reguera¹, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Raul Fernandez¹, Ivan Ferraz Amaro⁶, Jose Luis Hernandez¹ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital de Sierrallana, Santander, Spain, ⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].